Stocks Health care IBIO

NASDAQ · Health care

iBio, Inc. (IBIO)

iBio, Inc. reported revenue of $100K in fiscal 2026, down 75.0% from a year earlier. It posted a net loss of $33M. In fiscal 2026 capital spending exceeded operating cash flow by $23.8M. At June 30, 2026 it held $56.4M in cash. Its latest periodic report to the SEC is the annual report (10-K) filed on August 28, 2026.

What iBio, Inc. does

iBio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IBIO.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Where IBIO ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What iBio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 14, 2026
   Investor disclosure 8-K
2. September 4, 2026
   Annual report to shareholders ARS
3. September 4, 2026
   Proxy statement DEF 14A
4. August 28, 2026
   Annual report 10-K · period to June 30, 2026
5. August 28, 2026
   Quarterly results 8-K
6. August 20, 2026
   Preliminary proxy statement PRE 14A
7. August 14, 2026
   Passive stake (5% or more) SCHEDULE 13G
8. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
9. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
10. August 13, 2026
    Passive stake changed SCHEDULE 13G/A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 4, 2026. Insider transactions on SEC

Insider trades

What the people running iBio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about IBIO

What does iBio, Inc. do?

iBio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IBIO.

Is iBio, Inc. profitable?

No. In fiscal 2026 it reported a net loss of $33M on revenue of $100K.

How much revenue does iBio, Inc. make?

In fiscal 2026 iBio, Inc. reported revenue of $100K. That is 75.0% less than a year earlier.

When did iBio, Inc. last report?

Its most recent periodic report is the annual report (10-K) filed on August 28, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 14, 2026.

Similar companies

Compare IBIO with

Compare IBIO with any company

Follow IBIO

Get an email when iBio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow IBIO: get an email when it files

Where the numbers come from

Financial figures are the values iBio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.